期刊
VACCINE
卷 41, 期 9, 页码 1589-1601出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2023.01.033
关键词
Adjuvant; Formulation stability; Vaccine efficacy; dmLT; Mucosal immunity; ETEC; Polio
The stability of vaccine formulation is crucial to its efficacy. Biochemical evaluations provide information on composition and thermal stability, but animal models are needed to validate efficacy. This study assessed formulations of the mucosal adjuvant dmLT and found that immunization route and co-administered antigen had a greater impact on vaccine immunogenicity than dmLT formulation stability.
A key aspect to vaccine efficacy is formulation stability. Biochemical evaluations provide information on optimal compositions or thermal stability but are routinely validated by ex vivo analysis and not efficacy in animal models. Here we assessed formulations identified to improve or reduce stability of the mucosal adjuvant dmLT being investigated in polio and enterotoxigenic E. coli (ETEC) clinical vaccines. We observed biochemical changes to dmLT protein with formulation or thermal stress, including aggregation or subunit dissociation or alternatively resistance against these changes with specific buffer compositions. However, upon injection or mucosal vaccination with ETEC fimbriae adhesin proteins or inactivated polio virus, experimental findings indicated immunization route and co-administered antigen impacted vaccine immunogenicity more so than dmLT formulation stability (or instability). These results indicate the importance of both biochemical and vaccine-derived immunity assessment in formulation optimization. In addition, these studies have implications for use of dmLT in clinical settings and for delivery in resource poor settings. (c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据